The Role of Shear Wave Elastography to Evaluate Liver Stiffness in Patients with Fatty Liver Diagnosed on B Mode Ultrasonography in Patient with No History of Alcohol Consumption

Background: Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent condition associated with hepatic steatosis in the absence of significant alcohol consumption. While B-mode ultrasound is commonly used for diagnosis, it cannot quantify liver fibrosis—a crucial determinant of prognosis. Shear wave elastography (SWE) offers a non-invasive method to assess liver stiffness and potentially detect early fibrosis. Materials and Methods: The study was undertaken from March 2025 to august 2025 after obtaining Institutional Review Board (IRB) approval in patients referred to the department of Radio diagnosis, Narendra Modi Medical College & L.G hospital, Ahmedabad. The study population consisted first 100 patients with no history of alcohol consumption were diagnosed having fatty liver on B mode ultrasound and undergone shear wave elastography over 6 months. Liver stiffness values were recorded using a Mindray Resona I9 ultrasound machine. Results: In this study of 100 patients, 60 patients were male while 40 patients were female. The most common age group affected was 40-49 years.Fatty liver grading on B mode ultrasound revealed 50 patients (50.0%)in Grade I, 35 patients (35.0%) in Grade II, and 15 patients (15.0%) in GradeIII. SWE measurements showed distinct ranges: Grade I (5.04 ± 0.65 kPa), Grade II (6.99 ± 0.80 kPa), and Grade III (9.74 ± 0.77 kPa). A positive correlation was observed between fatty liver grading on B mode ultrasound and SWE values (r = 0.912, p < 0.001). Conclusion: Shear wave elastography demonstrates excellent correlation with B-mode fatty liver grading in NAFLD patients. The mean SWE values observed in our study (Grade I: 5.04 kPa, Grade II: 6.99 kPa, Grade III: 9.74 kPa) demonstrate a clear stepwise progression that mirrors the expected increase in liver stiffness with advancing fatty liver disease, enabling noninvasive fibrosis risk stratificationwithout liver biopsy.